Related references
Note: Only part of the references are listed.Effect of an Electronic Medication Reconciliation Application and Process Redesign on Potential Adverse Drug Events A Cluster-Randomized Trial
Jeffrey L. Schnipper et al.
ARCHIVES OF INTERNAL MEDICINE (2009)
Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors
Encouse B. Golden et al.
BLOOD (2009)
Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy
Kunihiro Suzuki et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
Thomas P. Ahern et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Emerging Significance of Flavonoids as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Tripta Bansal et al.
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES (2009)
Inflammation and altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice
G. R. Robertson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Role of ATP-Binding Cassette (ABC) Transporters in Interactions Between Natural Products and Drugs
Adorjan Aszalos
CURRENT DRUG METABOLISM (2008)
Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
Shu-Feng Zhou
CURRENT DRUG METABOLISM (2008)
Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4
Shu-Feng Zhou
CURRENT PHARMACEUTICAL DESIGN (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Pia Wegman et al.
BREAST CANCER RESEARCH (2007)
Drug interactions in cancer therapy
Charity D. Scripture et al.
NATURE REVIEWS CANCER (2006)
The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5
HL Lin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Effects of dietary chemopreventive phytochemicals on P-glycoprotein function
T Nabekura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Assessing medication adherence in the elderly - Which tools to use in clinical practice?
EJ MacLaughlin et al.
DRUGS & AGING (2005)
Herbal remedies in the United States: Potential adverse interactions with anticancer agents
A Sparreboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Effects of food on the clinical pharmacokinetics of anticancer agents - Underlying mechanisms and implications for oral chemotherapy
BN Singh et al.
CLINICAL PHARMACOKINETICS (2004)
Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters
A Di Pietro et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2002)
Inhibition of P-glycoprotein transport function by grapefruit juice psoralen
EJ Wang et al.
PHARMACEUTICAL RESEARCH (2001)
Pharmacogenomics: Unlocking the human genome for better drug therapy
HL McLeod et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Clinical-pharmacological strategies to assess drug interaction potential during drug development
J Kuhlmann et al.
DRUG SAFETY (2001)
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
D Dürr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Drug interactions in palliative care
SA Bernard et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
